3,4‐diaminopyridine base effectively treats the weakness of Lambert‐Eaton myasthenia
| Autor: | Jau Shin Lou, Vern C. Juel, Tai Xie, Donald B. Sanders, Laura R. Jacobus, Yadollah Harati, Amanda Peltier, Valentin Demmel, Tessa Marburger, Robert M. Pascuzzi, David P. Richman, Kathy L. Aleš, A. Gordon Smith, David P. Jacobus |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Weakness Amifampridine Physiology 3 4‐diaminopyridine efficacy ELS Placebo timed up‐and‐go 03 medical and health sciences Cellular and Molecular Neuroscience Drug withdrawal 0302 clinical medicine Clinical Research Physiology (medical) medicine Lambert‐Eaton syndrome Young adult Adverse effect LEMS Eaton‐Lambert syndrome Lambert‐Eaton myasthenia business.industry clinical trial medicine.disease Clinical trial 030104 developmental biology Anesthesia Lambert‐Eaton myasthenic syndrome LES Neurology (clinical) amifampridine medicine.symptom business Lambert-Eaton myasthenic syndrome 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Muscle & Nerve |
| ISSN: | 1097-4598 0148-639X |
| Popis: | Introduction: 3,4‐diaminopyridine has been used to treat Lambert‐Eaton myasthenia (LEM) for 30 years despite the lack of conclusive evidence of efficacy. Methods: We conducted a randomized double‐blind placebo‐controlled withdrawal study in patients with LEM who had been on stable regimens of 3,4‐diaminopyridine base (3,4‐DAP) for ≥ 3 months. The primary efficacy endpoint was >30% deterioration in triple timed up‐and‐go (3TUG) times during tapered drug withdrawal. The secondary endpoint was self‐assessment of LEM–related weakness (W‐SAS). Results: Thirty‐two participants were randomized to continuous 3,4‐DAP or placebo groups. None of the 14 participants who received continuous 3,4‐DAP had > 30% deterioration in 3TUG time versus 72% of the 18 who tapered to placebo (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text